Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1130-1137

  Crilly, Anne ^a   Robertson, Susan E ^a   Reilly, James H ^a   Gracie, J Alastair ^a   Lai, Wen Qi ^b   Leung, Bernard P ^a,b   Life, Paul F ^c   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INH 0061; INH 0062; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; INFLAMMATION MEDIATORS; PHOSPHODIESTERASE 4 INHIBITORS; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE; SYNOVITIS; T-LYMPHOCYTES;

EID: 79955839715     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.134825     Document Type: Article

References (38)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 ; 423 : 356-61. (Pubitemid 40852711) (Pubitemid 40852711)
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007 ; 7 : 429-42. (Pubitemid 46834849) (Pubitemid 46834849)
3. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008 ; 118 : 3537-45.
4. Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol 2008 ; 20 : 257-62. (Pubitemid 351483313) (Pubitemid 351483313)
5. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003 ; 370 : 1-18. (Pubitemid 36259414) (Pubitemid 36259414)
6. Ross SE, Williams RO, Mason LJ, et al. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997 ; 159 : 6253-9. (Pubitemid 127471567) (Pubitemid 127471567)
7. Francischi JN, Yokoro CM, Poole S, et al. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol 2000 ; 399 : 243-9. (Pubitemid 30407047) (Pubitemid 30407047)
8. Ozegbe P, Foey AD, Ahmed S, et al. Impact of cAMP on the T-cell response to type II collagen. Immunology 2004 ; 111 : 35-40. (Pubitemid 38091048) (Pubitemid 38091048)
9. Peter D, Jin SL, Conti M, et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007 ; 178 : 4820-31. (Pubitemid 46595264) (Pubitemid 46595264)
10. Kasyapa CS, Stentz CL, Davey MP, et al. Regulation of IL-15-stimulated TNF-alpha production by rolipram. J Immunol 1999 ; 163 : 2836-43. (Pubitemid 29399213) (Pubitemid 29399213)
11. Jimenez JL, Punzón C, Navarro J, et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001 ; 299 : 753-9.
12. Layseca-Espinosa E, Baranda L, Alvarado-Sánchez B, et al. Rolipram inhibits polarization and migration of human T lymphocytes. J Invest Dermatol 2003 ; 121 : 81-7. (Pubitemid 36900458) (Pubitemid 36900458)
13. Seldon PM, Barnes PJ, Meja K, et al. Suppression of lipopolysaccharide- induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995 ; 48 : 747-57.
14. Link A, Selejan S, Maack C, et al. Phosphodiesterase 4 inhibition but not betaadrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock. Crit Care 2008 ; 12 : R159.
15. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001 ; 297 : 267-79. (Pubitemid 32242587) (Pubitemid 32242587)
16. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007 ; 62 : 1081-7. (Pubitemid 350206202)
17. Heystek HC, Thierry AC, Soulard P, et al. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003 ; 15 : 827-35. (Pubitemid 36827071) (Pubitemid 36827071)
18. McCahill AC, Huston E, Li X, et al. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb Exp Pharmacol 2008 ; 186 : 125-66.
19. Foey AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNFalpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003 ; 5 : R317-28.
20. Lunniss CJ, Cooper AW, Eldred CD, et al. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett 2009 ; 19 : 1380-5.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31 : 315-24. (Pubitemid 18091653) (Pubitemid 18091653)
22. Sebbag M, Parry SL, Brennan FM, et al. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factoralpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997 ; 27 : 624-32. (Pubitemid 27110572) (Pubitemid 27110572)
23. Brennan F M, Hayes AL, Ciesielski CJ, et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 2002 ; 46 : 31-41. (Pubitemid 34121648) (Pubitemid 34121648)
24. McInnes IB, Leung BP, Sturrock RD, et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997 ; 3 : 189-95. (Pubitemid 27064704) (Pubitemid 27064704)
25. Burger D, Dayer JM. The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res 2002 ; 4 (Suppl 3) : S169-76.
26. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010 ; 12 : R107.
27. Haringman JJ, Smeets TJ, Reinders-Blankert P, et al. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 2006 ; 65 : 294-300. (Pubitemid 43268215) (Pubitemid 43268215)
28. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005 ; 52 : 710-21. (Pubitemid 40365092) (Pubitemid 40365092)
29. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008 ; 58 : 1931-9. (Pubitemid 351988084) (Pubitemid 351988084)
30. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti- tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008 ; 67 : 1516-23.
31. Emery P, McInnes IB, van Vollenhoven R, et al. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008 ; 47 : 392-8.
32. Foey A, Green P, Foxwell B, et al. Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res 2002 ; 4 : 64-70. (Pubitemid 34100491) (Pubitemid 34100491)
33. Laffón A, García-Vicuña R, Humbría A, et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991 ; 88 : 546-52.
34. Brennan FM, Chantry D, Jackson AM, et al. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989 ; 2 (Suppl) : 177-86.
35. Yamamura Y, Gupta R, Morita Y, et al. Effector function of resting T cells: activation of synovial fibroblasts. J Immunol 2001 ; 166 : 2270-5. (Pubitemid 32173457) (Pubitemid 32173457)
36. Tran CN, Lundy SK, White PT, et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007 ; 171 : 1588-98. (Pubitemid 350158319) (Pubitemid 350158319)
37. Meinecke I, Rutkauskaite E, Gay S, et al. The role of synovial fibroblasts in mediating joint destruction in rheumatoid arthritis. Curr Pharm Des 2005 ; 11 : 563-8. (Pubitemid 40277868) (Pubitemid 40277868)
38. Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010 ; 184 : 3336-40.